Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Mantle-Cell 7Lymphoma, Follicular 5Lymphoma, B-Cell 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, Non-Hodgkin 3Lymphoma, Large B-Cell, Diffuse 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, B-Cell, Marginal Zone 2Hematologic Neoplasms 2Burkitt Lymphoma 2Waldenstrom Macroglobulinemia 1Plasmablastic Lymphoma 1Myelodysplastic Syndromes 1Lymphoma, T-Cell 1Lymphoma, Primary Effusion 1Lymphoma, Large-Cell, Anaplastic 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Hairy Cell 1Hodgkin Disease 1Hematopoietic and Lymphoid System Neoplasm 1HIV Infections 1Composite Lymphoma 1Blast Crisis 1

Interventions

Rituximab 1Lenalidomide 1CT-P10 1ALX148 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Composite Lymphoma × CT-P10 × Clear all
NCT05025800 2026-03-20

ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
47 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Composite Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡